Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

Start-up’s MR1T cell therapy designed to address broader range of cancers than CAR T, TCR therapies

Versant’s Ridgeline incubator in Basel has launched Matterhorn with an off-the-shelf MR1T cell therapy designed to address a broader range of cancers than CAR T and TCR therapies. The company raised a $30 million series A round on Wednesday to take its first program into the clinic.

Matterhorn Biosciences AG licensed IP covering the use of MR1-restricted T cells in cancer immunotherapy from CSO Lucia Mori and fellow co-founder Gennaro

Read the full 698 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE